Trevi Therapeutics to Participate in Upcoming May Events

Rhea-AI Summary

Trevi Therapeutics (Nasdaq: TRVI) announced senior management will participate in three investor events in May 2026: an Investor & Analyst Day in New York on May 7, a Bank of America Global Healthcare Conference presentation in Las Vegas on May 12, and an ATS‑aligned data highlights event in Orlando on May 18.

Registration details include virtual webcasts and an IR email for the ATS event.

News Market Reaction – TRVI

+1.55%

+1.55% Session close to close

In the Apr 24 session, TRVI gained 1.55%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement outlines a series of May investor and conference events, including a May 7 Investo...

Analysis

This announcement outlines a series of May investor and conference events, including a May 7 Investor and Analyst Day and presentations at a major healthcare conference. It follows recent financings and 2025 results that funded Haduvio’s planned Phase 3 and Phase 2b trials. Investors may focus on how these forums elaborate clinical plans, capital deployment, and timelines. Key dates like May 7, May 12–13, and May 18 frame near-term catalysts for additional information.

Key Figures

Investor & Analyst Day: May 7, 2026 Analyst Day time: 10:00 a.m. to 12:00 p.m. ET BofA conference dates: May 12–13, 2026 +3 more

6 metrics

Investor & Analyst Day May 7, 2026 Trevi Therapeutics Investor and Analyst Day date

Analyst Day time 10:00 a.m. to 12:00 p.m. ET Duration of May 7, 2026 Investor and Analyst Day

BofA conference dates May 12–13, 2026 Bank of America Global Healthcare Conference 2026 dates

BofA presentation time 5:15 p.m. to 5:30 p.m. PT Corporate presentation slot on May 12, 2026

ATS data event date May 18, 2026 Trevi data highlights event during ATS 2026

ATS data event time 11:30 a.m. to 1:15 p.m. ET Duration of May 18, 2026 data highlights event

Historical Context

5 past events · Latest: Apr 20 (Neutral)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Apr 20	Equity offering closing	Neutral	-5.1%	Closed underwritten offering of 13.34M shares at $13.00, raising $173M.
Apr 16	Offering pricing	Neutral	+4.8%	Priced 11.6M-share offering at $13.00 for ~$150M gross proceeds.
Apr 16	Offering launch	Neutral	+4.8%	Announced proposed $150M offering with $22.5M underwriter option.
Apr 01	Investor events notice	Neutral	-2.9%	Outlined April–May investor conferences and May 7 Analyst Day.
Mar 17	Earnings and pipeline	Neutral	-4.5%	Reported 2025 results and detailed plans for Phase 3 and 2b trials.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent financings and corporate updates have typically led to modest single‑digit moves, with several negative reactions following offerings and earnings, and small declines after prior event-participation announcements.

Recent Company History

Over the last few months, TRVI has focused on funding and advancing Haduvio. In mid‑April, it launched and closed an underwritten offering at $13.00 per share, raising about $173 million, following earlier offering announcements that saw mixed single‑digit price moves. A March 17 earnings update highlighted $188.3 million in year‑end cash and plans for multiple Phase 3 and Phase 2b trials. An April 1 notice of upcoming investor events led to a modest -2.93% move. Today’s May events notice fits this pattern of ongoing investor-engagement communications.

Key Terms

idiopathic pulmonary fibrosis (ipf), interstitial lung disease (non-ipf ild), refractory chronic cough (rcc), oral nalbuphine er

4 terms

idiopathic pulmonary fibrosis (ipf) medical

"chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial"

A chronic lung disease in which the tissue of the lungs gradually becomes scarred and stiff, making it harder to breathe and get enough oxygen. For investors, IPF matters because it drives demand for treatments, shapes the commercial opportunity and clinical trial risk for drug developers, and can influence a company’s regulatory milestones and long‑term revenue potential; think of it as a market shaped by urgent medical need and high development risk.

interstitial lung disease (non-ipf ild) medical

"pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory"

A group of lung conditions that inflame or scar the thin tissue between air sacs, excluding idiopathic pulmonary fibrosis (IPF). Think of the lungs’ fine internal scaffold becoming thick or stiff, which makes breathing less efficient; different causes and severities fall under this label. Investors watch non‑IPF ILD because it defines patient populations, treatment needs, clinical trial design, and potential market size for therapies and diagnostics.

refractory chronic cough (rcc) medical

"interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC), today"

Refractory chronic cough is a long-lasting cough that continues for months despite standard treatments and after known causes have been evaluated and managed. For investors, it represents a clear unmet medical need—like a smoke alarm that keeps sounding after the fire is out—which can drive demand for new therapies, influence clinical trial activity, shape regulatory attention, and create commercial opportunities in diagnostics and specialty medicines.

oral nalbuphine er medical

"developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment"

An oral nalbuphine ER is a slow‑release pill form of nalbuphine, an opioid pain medicine that activates some pain‑blocking pathways while dampening others, which can lower certain side effects and abuse risk compared with traditional opioids. For investors, it signals a product with potential market demand for longer‑lasting, outpatient pain control, but its commercial value depends on clinical benefits, regulatory approval, patent protection and how payers and prescribers view its safety and cost — like a timed-release version of a familiar pain drug.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

NEW HAVEN, Conn., April 23, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC), today announced that senior management will participate in several upcoming events in May.

Trevi Therapeutics Investor and Analyst Day
May 7, 2026, Midtown New York, New York
10:00 a.m. to 12:00 p.m. ET, followed by lunch and open discussions
Representatives: Trevi senior management will be joined by key opinion leaders in chronic cough in IPF/ILD and RCC
To register for the virtual webcast, click here. 

Bank of America Global Healthcare Conference 2026
May 12-13, 2026, Las Vegas, Nevada
Corporate Presentation: May 12, 5:15 p.m. to 5:30 p.m. PT (8:15 p.m. to 8:30 p.m. ET)
Trevi Representatives: Jennifer Good, President and CEO, and David Hastings, CFO
To register for the virtual webcast, click here. 

Trevi Therapeutics: Data Highlights from Trevi’s ATS 2026 Presentations
May 18, 2026, Orlando, Florida
11:30 a.m. to 1:15 p.m. ET
Featuring: Philip Molyneaux, MD, PhD, Professor of Pulmonary Medicine at the Royal Brompton Hospital, and James Cassella, Ph.D., CDO, Trevi Therapeutics
This investor and analyst event will take place in-person, at the same time as the American Thoracic Society (ATS) 2026 International Conference. To register for the event, email IR@trevitx.com.

About Trevi Therapeutics, Inc.
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine extended-release for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC). Haduvio is the first and only investigational therapy to show a statistically-significant reduction in cough frequency in clinical trials across both patients with IPF-related chronic cough and in patients with RCC. Haduvio acts on the cough reflex arc both centrally and peripherally as a kappa agonist and a mu antagonist (KAMA), targeting opioid receptors that play a key role in controlling chronic cough. Nalbuphine is not currently scheduled by the U.S. Drug Enforcement Agency.

Chronic cough in patients with IPF and non-IPF ILD is a condition with high unmet need and no FDA-approved therapies. There are ~140,000 U.S. patients with IPF, and two-thirds of these patients are faced with uncontrolled chronic cough. Additionally, there are ~228,000 U.S. patients with non-IPF ILD, with 50-60% having uncontrolled chronic cough. The impact of chronic cough is significant, with patients coughing up to 1,500 times per day. This consistent cough, and any associated damage, may lead to a higher risk of morbidity and mortality, including worsening disease, a higher risk of progression, increased respiratory hospitalizations, and a decline in patients' quality of life.

RCC is a condition with high unmet need and no FDA-approved therapies. RCC is defined as a persistent cough lasting >8 weeks despite treatment for an underlying condition (i.e., asthma, gastroesophageal reflux disease, non-asthmatic eosinophilic bronchitis, upper airway cough syndrome, or post-nasal drip) and includes unexplained chronic cough. There are ~2-3 million U.S. patients with RCC, and it is believed to be associated with cough reflex hypersensitivity involving both the central and peripheral nervous systems. RCC is highly debilitating and may impact patients physically, psychologically, and socially.

Trevi intends to propose Haduvio as the trade name for oral nalbuphine ER. Its safety and efficacy have not been evaluated by any regulatory authority.

For more information, visit www.TreviTherapeutics.com and follow Trevi on X (formerly Twitter) and LinkedIn.

Investor Contact
Jonathan Carlson
Trevi Therapeutics, Inc.
(203) 654 3286
IR@trevitx.com

Media Contact
Rosalia Scampoli
914-815-1465
rscampoli@marketcompr.com

FAQ

When is Trevi Therapeutics' Investor and Analyst Day for TRVI in May 2026?

Trevi's Investor and Analyst Day is scheduled for May 7, 2026 in Midtown New York from 10:00 a.m. to 12:00 p.m. ET, followed by lunch and open discussions. According to the company, key opinion leaders will join management for sessions.

What time and date is Trevi presenting at the Bank of America Global Healthcare Conference (TRVI)?

Trevi will present on May 12, 2026 at the Bank of America Global Healthcare Conference in Las Vegas from 5:15 p.m. to 5:30 p.m. PT (8:15 p.m. to 8:30 p.m. ET). According to the company, CEO Jennifer Good will attend.

What is the Trevi Therapeutics ATS 2026 event on May 18, 2026 and who will present?

Trevi's ATS‑aligned event is on May 18, 2026 in Orlando from 11:30 a.m. to 1:15 p.m. ET, featuring Philip Molyneaux, MD, PhD, and James Cassella, PhD. According to the company, it will highlight Trevi's ATS 2026 data presentations.

How can investors register for Trevi Therapeutics (TRVI) virtual webcasts for the May events?

Investors can register for the virtual webcasts via the event links provided by Trevi for the Investor Day and Bank of America presentation. According to the company, webcast registration links are available for those specific May events.

Who from Trevi Therapeutics will represent the company at the May 2026 investor events (TRVI)?

Trevi representatives include senior management at the May 7 Investor Day and Jennifer Good, President and CEO, and David Hastings, CFO, at the Bank of America presentation. According to the company, James Cassella and external KOLs will appear at other May events.